# UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors

> **NCT06760117** · PHASE1 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 39 (estimated)

## Conditions studied

- Pediatric Solid Tumor

## Interventions

- **DRUG:** Irinotecan (CPT-11)
- **DRUG:** Temozolomide (TMZ)
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT06760117
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760117, "UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06760117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*